What is Interstitial Cystitis (Painful Bladder Syndrome)?
Currently in the field of urology, one of the most significant health issues profoundly impacting the quality of life, particularly in women, is Painful Bladder Syndrome, otherwise known as Interstitial Cystitis (IC). This pathology, characterized by an incessant urge to void, severe pain associated with bladder fullness, and which essentially forces the patient's life into a vicious cycle, no longer has to be a formidable nightmare, thanks to our current knowledge and multi-disciplinary, advanced-technology therapeutic options.
What is the Fundamental Etiology of the Disease?
Although the precise etiology of interstitial cystitis remains to be fully elucidated, structural microscopic deteriorations in the bladder lining elucidate the pathophysiological process. A Glycosaminoglycan (GAG) layer coats the inner surface (mucosa) of the bladder, serving as a protective barrier. Following the degradation of this layer or the collapse of its restorative mechanisms, the chemical constituents of urine come into direct contact with the highly sensitive C nerve fibers located immediately beneath the mucosa. This exposure triggers an intense sensation of distension and pain in the bladder, thereby inducing an urgent need to micturate. It is postulated that successive urinary tract infections (cystitis) precipitate damage within this layer and provoke inflammatory reactions at the nerve endings, predisposing the tissue to this condition.
What are the Clinical Manifestations of Interstitial Cystitis?
If you are experiencing the following clinical symptoms, a diagnosis of Interstitial Cystitis should be highly suspected:
- A burning, stinging sensation, and occasionally severe pain accompanied by urinary urgency commencing from the moment urine begins to accumulate in the bladder.
- Transient relief of pain following micturition (bladder emptying).
- An imperative need to void exceeding 7-8 times, sometimes reaching 20-30 times during the day, and nocturia (awakening to void more than 3-4 times per night).
- Urinalysis and urine cultures yielding completely sterile results in 95% of cases (absence of pathogenic microorganisms or erythrocytes).
A Prevalent Fallacy: Cessation of Water Intake
Patients afflicted with painful bladder syndrome frequently reduce their water consumption to mitigate bladder pain and avoid frequent micturition. However, this constitutes a substantial clinical error! As water intake diminishes, the concentration of the urine produced by the kidneys and its chemical density concomitantly increase. Urine with a higher concentration of chemicals exacerbates the irritation of the nerve endings, whose protective barrier has been compromised, thereby intensifying the pain. Copious hydration dilutes the urine, consequently attenuating this irritation.
How is an Accurate Diagnosis Established?
Following a comprehensive clinical evaluation and detailed anamnesis, the most definitive diagnostic modality is cystoscopy (endoscopy) and hydrodistention (fluid engorgement of the bladder) performed under anesthesia. During this procedure, the following parameters are evaluated:
- Petechial Hemorrhages (Glomerulations): Punctate hemorrhages manifesting on the mucosa following the distention and subsequent evacuation of the bladder.
- Hunner's Lesions (Ulcers): Severe mucosal ulcerations observed in advanced cases.
- Bladder Capacity: While normal physiological bladder capacity under anesthesia is 700-800 cc, it may be drastically reduced to 300-400 cc, or even 150 cc, in patients with interstitial cystitis.
Management of Interstitial Cystitis:
Contemporary and Advanced Therapeutic Approaches
The therapeutic algorithm for the disease is stratified contingent upon the severity of the symptoms and the objective bladder capacity:
Oral and Intravesical Pharmacotherapy:
Pentosan Polysulfate Sodium (Elmiron) is administered to restore the GAG layer, and Amitriptyline derivatives are utilized for neuromodulatory pain management. Furthermore, direct intravesical instillations (e.g., Heparin) are targeted toward mucosal restoration.
Dietary Modification:
Acid-restricted diets are implemented, advocating the avoidance of acidic beverages, coffee, tea, tomatoes, and foods with high Vitamin C content. However, in chronic, refractory cases, dietary adjustments and oral pharmacotherapy alone may prove inadequate.
Combined Prolonged Anti-Inflammatory Hydrodistention and Pudendal Nerve Blockade:
In cases refractory to oral and intravesical therapies, a bilateral Pudendal Nerve Blockade (injection of corticosteroids and long-acting local anesthetics) is performed concomitantly with a prolonged anti-inflammatory hydrodistention procedure under anesthesia. This multimodal approach yields a highly significant amelioration in pain scores and nocturia in over 80% of patients, and the clinical success achieved can be sustained long-term or permanently.
Robotic Surgery in Advanced Stages:
In a highly restricted cohort of patients whose bladder capacity has irreversibly diminished (fibrotic bladder) and who derive no benefit from alternative modalities, Robotic Surgery is indicated. The bladder capacity is augmented via an intestinal patch (Augmentation Cystoplasty) whilst preserving the bladder base. In exceptionally advanced cases, the diseased bladder is entirely excised, and an orthotopic neobladder is constructed from the small intestine. Through the minimally invasive (laparoscopic/robotic) approach afforded by robotic surgery, the morbidities associated with open surgery are circumvented, and patients achieve complete convalescence.
Prof. Dr. Tibet Erdoğru
Urology
